Correction: HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers.
[This corrects the article DOI: 10.1371/journal.pone.0285251.].
Saved in:
Main Author: | PLOS ONE Staff |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2024-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0315773 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01) -
Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer
by: Taeyeong Kim, et al.
Published: (2025-01-01) -
Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers
by: Femke A. I. Ehlers, et al.
Published: (2025-01-01) -
The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status
by: Sanaa Gamrani, et al.
Published: (2023-01-01) -
Comparison between Real-Time Quantitative PCR Detection of HER2 mRNA Copy Number in Peripheral Blood and ELISA of Serum HER2 Protein for Determining HER2 Status in Breast Cancer Patients
by: Maria Savino, et al.
Published: (2009-01-01)